[12] Patent
[11] Patent No.:GC0007652  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126501
Date of the Decision to Grant the Patent:25/Apr/2018

[21] Application No.:GCC/P/2006/28406

[22] Filing Date:22/2/2006

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
23/2/2005
60/655,277

[72] Inventors:1- Mika K. Derynck،2- Stephen M. Kelsey

[73] Owner: GENENTECH, INC., 1 DNA Way, California 94080, South San Francisco, USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K36/395, A61P35/00 (2006.01)

[56] Cited Documents:

-WO 2004008099 A2 (GENETECH, INC' KOLL, HANS; BOSSENMAAIER, BRIGHT; MUELLER, HANS-JOACHIM) 22 January 2004
-WO 0100238 A1 (GENETECH, INC; SLOAN-KETTERING INSTITUE FOR CANCER RESEARCH) 04 January 2001
 
Examiner: PH. Mohammad S. AlMousa

[54] EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
[57] Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient’s cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
No. of claims: 10     No. of figures: 23


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.